Join
Live feed
·
PRReleasevia Quantisnow
GSK plc logo
Myriad Genetics Inc. logo
Personalis Inc. logo
+1

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

ByQuantisnow·Wall Street's wire, on your screen.
GSK· GSK plcMYGN· Myriad Genetics Inc.PSNL· Personalis Inc.QGEN· Qiagen N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GSK (GSK plc), MYGN (Myriad Genetics Inc.), PSNL (Personalis Inc.) and more on Quantisnow.